BeOne Medicines to Pay RMB446 Million Tax Adjustment, Expense Slated for FY2026

Bulletin Express06-26

BeOne Medicines Ltd. (BeOne) reported that a wholly-owned Chinese subsidiary has reached an agreement with the local tax authority to revise previously filed returns, leading to an income-tax payment—inclusive of late-payment surcharges—of approximately RMB446.00 million.

The company confirmed: • Timing: The payment will be settled promptly, with no administrative penalty attached. • Accounting treatment: The entire RMB446.00 million will be recorded as income-tax expense in BeOne’s fiscal-year 2026 financial statements. • Impact: Management stated the adjustment does not constitute a prior-period accounting error; therefore, no retrospective restatement of historical financials is required. The ultimate effect on FY2026 net income will be determined upon completion of the audited results for the year ending 31 December 2026. • Outlook: BeOne does not expect the tax settlement to have a material adverse impact on its financial condition, long-term operating capabilities, or routine business activities.

The announcement was authorized by Chairman John V. Oyler and released in Hong Kong on 26 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159743193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159743193","market":"hk","top_or_hot":-1,"title":"BeOne Medicines to Pay RMB446 Million Tax Adjustment, Expense Slated for FY2026","media":"Bulletin Express","content":"<p>BeOne Medicines Ltd. (BeOne) reported that a wholly-owned Chinese subsidiary has reached an agreement with the local tax authority to revise previously filed returns, leading to an income-tax payment—inclusive of late-payment surcharges—of approximately RMB446.00 million.</p>\n<p>The company confirmed:\n• Timing: The payment will be settled promptly, with no administrative penalty attached.  \n• Accounting treatment: The entire RMB446.00 million will be recorded as income-tax expense in BeOne’s fiscal-year 2026 financial statements.  \n• Impact: Management stated the adjustment does not constitute a prior-period accounting error; therefore, no retrospective restatement of historical financials is required. The ultimate effect on FY2026 net income will be determined upon completion of the audited results for the year ending 31 December 2026.  \n• Outlook: BeOne does not expect the tax settlement to have a material adverse impact on its financial condition, long-term operating capabilities, or routine business activities.</p>\n<p>The announcement was authorized by Chairman John V. Oyler and released in Hong Kong on 26 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines to Pay RMB446 Million Tax Adjustment, Expense Slated for FY2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines to Pay RMB446 Million Tax Adjustment, Expense Slated for FY2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-26 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines Ltd. (BeOne) reported that a wholly-owned Chinese subsidiary has reached an agreement with the local tax authority to revise previously filed returns, leading to an income-tax payment—inclusive of late-payment surcharges—of approximately RMB446.00 million.</p>\n<p>The company confirmed:\n• Timing: The payment will be settled promptly, with no administrative penalty attached.  \n• Accounting treatment: The entire RMB446.00 million will be recorded as income-tax expense in BeOne’s fiscal-year 2026 financial statements.  \n• Impact: Management stated the adjustment does not constitute a prior-period accounting error; therefore, no retrospective restatement of historical financials is required. The ultimate effect on FY2026 net income will be determined upon completion of the audited results for the year ending 31 December 2026.  \n• Outlook: BeOne does not expect the tax settlement to have a material adverse impact on its financial condition, long-term operating capabilities, or routine business activities.</p>\n<p>The announcement was authorized by Chairman John V. Oyler and released in Hong Kong on 26 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1159743193","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159743193","pubTimestamp":1782468333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BeOne Medicines Ltd. (BeOne) reported that a wholly-owned Chinese subsidiary has reached an agreement with the local tax authority to revise previously filed returns, leading to an income-tax...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"BeOne Medicines将支付人民币4.46亿元的税收调整费用，预计将于2026财年支付","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeOne Medicines Ltd. (BeOne) reported that a wholly-owned Chinese subsidiary has reached an agreement with the local tax authority to revise previously filed returns, leading to an income-tax payment—inclusive of late-payment surcharges—of approximately RMB446.00 million.\nThe company confirmed:\n• Timing: The payment will be settled promptly, with no administrative penalty attached.  \n• Accounting treatment: The entire RMB446.00 million will be recorded as income-tax expense in BeOne’s fiscal-year 2026 financial statements.  \n• Impact: Management stated the adjustment does not constitute a prior-period accounting error; therefore, no retrospective restatement of historical financials is required. The ultimate effect on FY2026 net income will be determined upon completion of the audited results for the year ending 31 December 2026.  \n• Outlook: BeOne does not expect the tax settlement to have a material adverse impact on its financial condition, long-term operating capabilities, or routine business activities.\nThe announcement was authorized by Chairman John V. Oyler and released in Hong Kong on 26 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159743193","isCrawlerRequest":true}